United States - English - NLM (National Library of Medicine)

georgia respiratory homecare & medical equipment llc - oxygen (unii: s88tt14065) (oxygen - unii:s88tt14065) -

United States - English - NLM (National Library of Medicine)

georgia oxygen & home health - oxygen (unii: s88tt14065) (oxygen - unii:s88tt14065) -

United States - English - NLM (National Library of Medicine)

georgia pacific consumer products - benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y) - antiseptic to decrease bacteria on skin that could cause disease recommended for repeated use if irritation or redness develops.  if condition persists for more than 72 hours consult a doctor.

United States - English - NLM (National Library of Medicine)

georgia pacific consumer products - benzalkonium chloride 0.1% w/w - antiseptic - to decrease bacteria on skin that could cause disease - recommended for repeated use if irritation or redness develops.  if condition persists for more than 72 hours, consult a pysician

United States - English - NLM (National Library of Medicine)

bath & body works, inc. - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antiseptic decreases bacteria on hands. if irritation or redness develops.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

yue fong (m) sdn. bhd. - rhizoma anemarrhena asphodeloides bge.; radix trichosanthes kirilowii maxim; radix sophora flavescens ait.; radix scutellaria baicalensis george; radix platycodon grandiflorum (jacq.) a. dc.; radix peucedanum praeruptorum dunn; radix et rhizoma rheum palmatum l.; fructus gardenia jasminoides ellis; cortex phellodendron chinense -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

bty worldwide sdn.bhd. - rhizoma anemarrhena asphodeloides bge; radix trichosanthes kirilowii maxim; radix scutellaria baicalensis george; radix peucedanum praeruptorum dunn; radix et rhizoma rhei; herba andrographitis paniculata; fructus gardenia jasminoides ellis; bulbus fritillariae thunbergii; radix platycodon grandiflorum; radix sophora flavescens -

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - ezetimibe, quantity: 10 mg; simvastatin, quantity: 40 mg - tablet - excipient ingredients: croscarmellose sodium; lactose monohydrate; hypromellose; propyl gallate; microcrystalline cellulose; ferric oxide; butylated hydroxyanisole; magnesium stearate; ascorbic acid; citric acid monohydrate - adults (greater than or equal to 18 years),prevention of cardiovascular disease,ezetorin is indicated in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) taking their maximum tolerated dose of simvastatin and in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see section 5.1 pharmacodynamic properties - clinical trials),primary hypercholesterolaemia,ezetorin is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate:,? patients not appropriately controlled with a statin or ezetimibe alone. ? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),ezetorin is indicated in patients with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).,children and adolescents 10-17 years (pubertal status: boys tanner stage ii and above and girls who are at least one year post-menarche),heterozygous familial hypercholesterolaemia (hefh),ezetorin is indicated as adjunctive therapy to diet in adolescent patients (10-17 years old) with hefh where use of a combination product is appropriate:,? patients not appropriately controlled with a statin or ezetimibe alone. ? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),ezetorin is indicated in adolescent patients (10-17 years old) with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - simvastatin, quantity: 10 mg; ezetimibe, quantity: 10 mg - tablet - excipient ingredients: butylated hydroxyanisole; microcrystalline cellulose; lactose monohydrate; croscarmellose sodium; hypromellose; magnesium stearate; ferric oxide; propyl gallate; ascorbic acid; citric acid monohydrate - adults (greater than or equal to 18 years),prevention of cardiovascular disease,simtorsi is indicated in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) taking their maximum tolerated dose of simvastatin and in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see section 5.1 pharmacodynamic properties - clinical trials),primary hypercholesterolaemia,simtorsi is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate:,? patients not appropriately controlled with a statin or ezetimibe alone. ? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),simtorsi is indicated in patients with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).,children and adolescents 10-17 years (pubertal status: boys tanner stage ii and above and girls who are at least one year post-menarche),heterozygous familial hypercholesterolaemia (hefh),simtorsi is indicated as adjunctive therapy to diet in adolescent patients (10-17 years old) with hefh where use of a combination product is appropriate:,? patients not appropriately controlled with a statin or ezetimibe alone. ? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),simtorsi is indicated in adolescent patients (10-17 years old) with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - ezetimibe, quantity: 10 mg; simvastatin, quantity: 40 mg - tablet - excipient ingredients: propyl gallate; ferric oxide; croscarmellose sodium; microcrystalline cellulose; magnesium stearate; citric acid monohydrate; hypromellose; ascorbic acid; lactose monohydrate; butylated hydroxyanisole - adults (greater than or equal to 18 years),prevention of cardiovascular disease,simtorsi is indicated in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) taking their maximum tolerated dose of simvastatin and in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see section 5.1 pharmacodynamic properties - clinical trials),primary hypercholesterolaemia,simtorsi is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate:,? patients not appropriately controlled with a statin or ezetimibe alone. ? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),simtorsi is indicated in patients with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).,children and adolescents 10-17 years (pubertal status: boys tanner stage ii and above and girls who are at least one year post-menarche),heterozygous familial hypercholesterolaemia (hefh),simtorsi is indicated as adjunctive therapy to diet in adolescent patients (10-17 years old) with hefh where use of a combination product is appropriate:,? patients not appropriately controlled with a statin or ezetimibe alone. ? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),simtorsi is indicated in adolescent patients (10-17 years old) with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).